亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

格列美脲 CAS號(hào):93479-97-1

 
 
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 湖北隨州市付款后3天內(nèi)
型號(hào) CAS號(hào):93479-97-1
過期 長(zhǎng)期有效
更新 2020-07-28 09:00
 

隨州市紅旗化工有限公司

企業(yè)會(huì)員第15年
資料未認(rèn)證
保證金未繳納
  • 湖北-隨州市
  • 上次登錄 2023-06-07
  • 閆先生 (先生)   經(jīng)理
詳細(xì)說明
格列美脲
CAS號(hào):93479-97-1
化學(xué)名稱:1-(4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基)-乙基 [苯磺酰)-3-(反式-4-甲基環(huán)己基)] 尿
 熔點(diǎn):207-209℃   
有關(guān)物質(zhì): ≤1.0% 
分子式:C24H34N4O5S
標(biāo)準(zhǔn):企業(yè)標(biāo)準(zhǔn)
含量:≥99.0% 
性質(zhì):白色粉末 
用途:本品為第三代磺酰脲類長(zhǎng)效抗糖尿病藥,其作用機(jī)制是通過與胰腺β-細(xì)胞表面的磺酰脲受體(相對(duì)分子質(zhì)量為6.5×104的蛋白質(zhì))結(jié)合,此受體與ATP敏感的K+(KATP)通道相耦連,促使KATP通道關(guān)閉,引起細(xì)胞膜的去極化,使電壓依賴性鈣通道開放,Ga2+內(nèi)流而促使胰島素的釋放,并抑制肝葡萄糖的合成。
包裝規(guī)格:25kg/桶
舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
來氟米特 CAS號(hào): 75706-12-6 頭孢曲松鈉 CAS;74578-69-1 福多斯坦 CAS號(hào): 13189-98-5 克洛索隆 CAS;60200-06-8 磷酸吡哆醛 CAS號(hào): 54-47-7 4-甲基噻唑-5-甲醛 CAS號(hào): 82294-70-0 三氯苯噠唑 CAS:68786-66-3 5-乙酰水楊酸甲酯 CAS;16475-90-4
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |